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Abstract: Biofilms play an important role in infectious diseases. It has been estimated that most
medical infections are due to bacterial biofilms, and about 60–70% of nosocomial infections are also
caused by the formation of a biofilm. Historically, microalgae are an important source of bioactive
compounds, having novel structures and potential biological functions that make them attractive
for different industries such as food, animal feed, aquaculture, cosmetics, and pharmaceutical.
Several studies have described compounds produced by microalgae and cyanobacteria species with
antimicrobial activity. However, studies on the antibiofilm activity of extracts and/or molecules
produced by these microorganisms are scarce. Quorum-sensing inhibitor and anti-adherent agents
have, among others, been isolated from microalgae and cyanobacteria species. The use of tools
such as nanotechnology increase their power of action and can be used for preventing and treating
biofilm-related infections.
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1. Biofilms and Their Role in Infectious Diseases
Biofilms are defined as microbial communities of surface-attached cells embedded in a
self-produced extracellular matrix and play an important role in infectious diseases. Biofilm formation
is developed in three main stages: (i) attachment—the cells arrive to the surface and adhere to this
surface; (ii) growth and maturation—the cells begin to produce the exopolysaccharide that constitutes
the matrix and mature from microcolonies to multilayered cell clusters; (iii) detachment—the cells take
on a planktonic state and can thereby form biofilm in other settings [1]. (Figure 1)
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Bacteria inside a biofilm can be up to 1000-fold more resistant to antibiotics and can persist
after treatment with antibiotics. Several mechanisms of antimicrobial resistance have been described
in a biofilm: (i) poor diffusion of antibiotics through the polysaccharide matrix of the biofilm;
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(ii) physiological changes due to a slow growth rate and response to low oxygen, nutrient deprivation
or environmental stress; (iii) phenotypic changes of the cells forming the biofilm; (iv) quorum-sensing;
(v) the expression of efflux pumps; (vi) interchange of resistance genes among bacteria inside the
biofilm; and (vii) the presence of persister cells—small fractions of persistent bacteria that resist death
when exposed to antimicrobials [2]. In addition, these structures also allow biofilms to avoid the action
of the immune system and evade phagocytosis.
It has been estimated that most medical infections are due to bacterial biofilms, and about 60–70%
of nosocomial infections are also caused by the formation of a biofilm [3–5]. Biofilms are ubiquitous
and can be located in different parts of the body, associated or not with medical devices or prostheses,
causing different types of infections. Indwelling devices in which biofilm infections can be found
include: intravenous catheters, vascular prosthesis, prosthetic heart valves, urinary catheters, joint
prostheses and orthopedic fixation devices, peritoneal dialysis catheters, and intrauterine devices.
Infections not associated with foreign bodies include cystic fibrosis (CF), chronic obstructive pulmonary
disease, chronic otitis media, chronic sinusitis and chronic (diabetes) wound infections [3,4,6,7].
2. What is Needed to Fight Biofilms
Two important things are needed to fight biofilms: a diagnostic tool that can be used in clinical
settings, and new molecules active against biofilm formation and/or against a mature biofilm.
There is currently no standardized technique that can be routinely applied to determine whether
or not a pathogen forms biofilm. Thus, treatment is based on the susceptibility of planktonic bacteria.
Therefore, a rapid diagnostic tool able to determine if the isolated microorganism has the capacity to
form biofilm, together the development of adequate treatment guidelines for these cases, could be
avoid treatment failures in biofilm-related infections. In vitro and in vivo experiments have shown that
the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) for
biofilm bacterial cells are usually much higher (approximately 1–1000 times) than those of planktonic
bacterial cells [4]. Moreover, MIC and MBC values are not applicable in vivo for biofilm eradication
due to renal and hepatic toxicities. Therefore, a rapid diagnostic tool able to determine if the isolated
microorganism has the capacity to form biofilm, is needed in addition to the development of adequate
treatment guidelines for these cases in order to avoid treatment failures in biofilm-related infections.
The diagnosis of biofilm-related infections is complex and should combine a global
multidisciplinary perspective which considers clinical aspects and microbiological findings. Initially,
routine microbiological examinations including biopsies, culture, Gram staining, and susceptibility
tests are important when infection is associated with a foreign body. However, in many cases, these
tests are not sensitive enough to detect biofilm. Today, molecular analysis such 16S ribosomal RNA
polymerase chain reaction (PCR) (bacteria) or 18S and 28S rRNA PCR (fungi) together with sonication
of foreign body are effective complementary procedures in laboratories, due to the high sensitivity
of pathogen detection, especially when microscopy and culture studies are negative in patients with
clinical suspicion of biofilm infection [5].
Foreign bodies such as prostheses, urinary/venous catheters and prosthetic heart valves provide
an ideal surface for the formation of biofilm. Once biofilm is established, the use of antimicrobials and
immune response are not sufficient to eradicate the infection. In these cases, it is advisable to remove
and/or replace the medical device to reduce the bacterial density and allow combined antibiotic therapy
to be effective. However, in some cases such as in patients with central intravascular catheters, device
replacement can be problematic and the risk of surgical removal may be greater than the risk associated
with ineffective antibiotic treatment. In these cases, a treatment called locking is recommended, which
consists of instilling a solution of an anticoagulant such as heparin and antibiotic inside the catheter at
a concentration between 100 and 1000 times higher than the MIC of the microorganism responsible for
the catheter-associated infection for at least eight hours a day during days 10–14. The antibiotics most
commonly used in these cases are gentamicin, levofloxacin, cotrimoxazole, minocycline, teicoplanin,
and vancomycin [8,9].
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3. Prevention or Treatment of Biofilm Infections
Treatment of biofilm-related infections is a subject that requires further study. Several approaches
to biofilm treatment have been developed. For example, clarithromycin blocks the biofilm matrix in
Pseudomonas aeruginosa [10]. Ciprofloxacin reduces the overall thickness of the biofilm [11]. On the
other hand, combination therapy has been recommended for the treatment of biofilm-related infections.
Macrolides are one of the first antibiotics selected due to their high in vitro and in vivo antibiofilm
activity against Gram-negative bacteria by the inhibition of alginate (one of the components of the
matrix) production [12,13]. For example, the combinations of clarithromycin plus erythromycin [13] and
clarithromycin plus vancomycin have in vitro antibiofilm activity against P. aeruginosa [14]. However,
in the case of Gram-positive bacteria, macrolides enhance biofilm formation by the overexpression of
several genes related to biofilm formation such as icaA, atlE, fruA, pyrR, sarA, and sigB [15].
Unfortunately, antimicrobial therapy in infections associated with foreign bodies is not sufficient
due to the appearance of multidrug-resistant bacteria, including Gram-negative bacilli such as
P. aeruginosa, which is associated with mechanical ventilation-associated pneumonia, Escherichia coli
isolated from urinary tract catheter infection, and methicillin-resistant Staphylococcus aureus (MRSA)
associated with prosthetic joints infection and heart valves [5]. For this reason, the need for new
therapies to deal with this great problem is imperative.
According to these needs, several authors have focused their research on discovering “small
molecules” with antibiofilm activity [3] (Table 1). Specifically, in 2013 Cheng and colleagues described
the screening of more than 200,000 chemical compounds [16]. After screening 66,000 compounds
and natural products in 2011, Sambanthamoorthy and col. [17] identified a small molecule called
benzimidazole, which is able to inhibit biofilm formation by several Gram-negative and Gram-positive
bacterial pathogens, including P. aeruginosa and S. aureus. Another important small molecule is the
organic compound cis-2-decenoic acid isolate from P. aeruginosa that can inhibit biofilm development
by a number of bacteria, including E. coli, Klebsiella pneumoniae, Proteus mirabilis, Streptococcus pyogenes,
Bacillus subtilis, S. aureus, and Candida albicans [18]. (Figure 2)
Table 1. Small molecules with antibiofilm activity.
Molecule Mechanism Effect Ref.
Anti-virulence
compounds
Inhibition of gene expression of
virulence factors
Inhibition of biofilm formation by
S. aureus [19]
Anti-biofilm compounds Unknown Inhibition of biofilm formation byS. epidermidis [20]
Acyl Homoserine
Lactones (AHLs) Autoinducers-QS




Inhibition of biofilm formation by
S. aureus [22]
ABC-1 Inhibition of c-di-GMP-inducibletranscription




Indole and derivatives Oxidized indole metabolites Inhibition of biofilm formation by E. coli,P. aeruginosa, Staphylococcal species [23]
Carolacton
Affect the expression of two
component signal
transduction systems
Inhibition of biofilm formation by
S. mutans [24]
Chelators Interference with metal ion’s functionin biofilm formation
Inhibition of biofilm formation by
S. aureus [25]
Aryl rhodanines Unknown Inhibition of biofilm formation byS. aureus and S. epidermidis [26]
Cis-2-decenoic acid Unknown
Dispersion of biofilms by E. coli, K.
pneumoniae, P. mirabilis, S. pyogenes,
B. subtilis, S. aureus, and C. albicans
[18]
D-amino acids Unknown Inhibition of biofilm formation byS. aureus and P. aeruginosa [27]
N-acetylcysteine Interference with exopolysaccharideformation in biofilms
Inhibition of biofilm formation by
S. epidermidis [28]
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Figure 2. (a) Cyclic diguanylic acid (c-di-GMP), (b) 7-hydroxyindole, (c) N-acetylcysteine,
(d) cis-2-decenoic acid, (e) acyl homoserine lactones (AHLs), and (f) carolacton.
Another strategy to combat biofilms is by avoiding the adherence of bacteria to surfaces or medical
devices by bactericidal/bacteriost ic coating [29]. In this sense, cat t rs and prosthesis are coated
with antibiotics or silver. Ant biotics such as vancomycin are commo ly used. However, the use of
antibiotics can lead to the selection of antibiotic resistant strains and even induce biofilm formation [30].
Silver has been used due to its broad-spectrum antimicrobial activity determined by the availability of
the silver ion released to interact with the cell membranes of the microorganisms [31]. Nonetheless,
while silver coating on medical devices prevents surface attachment of bacteria, it can have genotoxic
and cytotoxic effects. On the other hand, anti-adhesion coatings such as silica colloids/silanexerogel,
among others, can prevent the formation of bacterial biofilms. However, the in vivo efficacy of these
coatings is still not clear due to the complexity of the interactions between coating surface with bacteria
and host proteins [3,16].
Nevertheless, although there are also other experimental approaches to combat biofilms such as
liposomes, bacterial interference, nanoparticles, hydrogels, iontophoresis, and bacteriophages, among
others. New molecules with antibacterial and antibiofilm activity that can be used in clinical practice
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are needed. For this reason, it is important to explore new sources to find new molecules for combating
biofilm-related infections.
Microalgae are one of the most promising sources of molecules/compounds with biological activity
not only because of their high diversity of species and niches in which they live but also due to their
high defence strategies against competitors and depredators.
4. Microalgae as a Source of Bioactive Compounds
In oceans, rivers, and lakes, microalgae represent an important group of microscopic and
unicellular organisms that have the ability to perform photosynthesis, producing about half of the
atmospheric oxygen [32].
The biodiversity of microalgae is enormous, and to date, only 50,000 species have been described
among the 200,000–800,000 species estimated to exist. The current classification system of microalgae
is based on different phenotypic characteristics such as morphology, photosynthetic pigments, cell
wall composition and structure, sexual cycles and more recently, genomic studies by the comparison of
5S, 18S, and 28S ribosomal RNA sequences [33].
Historically, microalgae are an important source of bioactive compounds with novel structures
and potential biological functions that make them attractive for different food, animal feed, aquaculture,
and cosmetics and pharmaceutical industries, among others [34–36] (Figure 3).
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Currently, the global production of microalgae and cyanobacteria is predominately aimed at
applications with high added value due to algal biomass containing pigments, proteins, toxins,
polyunsaturated fatty acids (PUFAs), polysaccharides, vitamins, and minerals, all of which are of
great interest in the preparation of natural products, as in food, cosmetics, and pharmaceutical
industries [37–39]. (Table 2 and Figure 4)
Table 2. Principal bioactive compounds extracted from microalgae.
Microalgae Bioactive Compounds Use Ref.
Arthrospira platensis Methanolic extracts ofexopolysaccharides Antioxidant [40]




PUFAs (n-3) (a) fatty acids,
chlorophyll




Chlorella ellipsoidea Zeaxanthin (b), violaxanthin




Chlorella minutissima Eicosapentaenoic acid (EPA) Food supplements [46]
Chlorella protothecoides Lutein, zeaxanthin,canthaxanthin
Health and cosmetic as UV
protection, antioxidant [47,48]
Chlorella pyrenoidosa Lutein, sulfatedpolysaccharide




peptide, oleic acid, Diethyl
phthalate (c), trimethyl
(4-tertbutyl phenoxy) silane
(d), chlorella vulgaris extracts
Antioxidant, antimicrobial,
antibiofilm, anti-ageing [49–51]

















lutein, β-carotene, oleic acid
Health and cosmetic as UV
protection, antioxidant [54]
Oscillatoria sp Oscillatoria sp. extract Antioxidant, antimicrobial,antibiofilm [51]






PUFAs (n-3) fatty acids, oleic
acid, linolenic acid,
palmitoleic acid
Food, health and cosmetics,
antimicrobial, antibiofilm [55]
Spirulina fusiformis Diacylglycerols Acylation stimulating protein [51]
Nostoclinckia/
Nostocspongiaeforme Borophycin, cryptophycin Anti-tumor compounds [56]
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Figure 4. Molecules with antibiofilm activity isolated from microalgae (a) omega-3 fatty acids (PUFAs),
(b) zeaxanthin, (c) diethyl phthalate, (d) trimethyl (4-tertbutyl phenoxy) silane, (e) linolenic acid,
(f) palmitic acid, and (g) Glucosyltransferase-SI.
Some of the main commercial microalgae products are PUFAs (a) used principally in the
pharmaceutical and nutritional industries. Species such as Chlorella sp., Spirulina sp., Dunaliella salina,
Ochromonas sp. and Chlamydomonas reinhardtii are a good source of these compounds [52].
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Polysaccharides are another promising type of compounds due to their abundance among
microalgae species. Several pharmaceutical, food and cosmetic industries use these compounds as
moisturizing, thickening, stabilizer and emulsifier agents. [37,57]. Several types of polysaccharides such
as homo-galactose, glucose, xylose, rhamnose, fucose and fructose showing antibacterial, antitumor,
and antiviral properties can be extracted using “green” extraction techniques from the microalgae
Gymnodinium pudicum and Chorella vulgaris [58–60].
The main microalgae species used in cosmetic products are Arthrospira sp, D. salina, and Chlorella
sp., because they are an important source of pigments and natural colour enhancers. Among these
isolated compounds, astaxanthin and carotenoid pigments are the most important for preventing
oxidative stress caused by UV radiation [45].
Taking into account the ability of microalgae to combat pathogenic bacteria found throughout
the different aquatic systems, they are considered one of the most important sources of antimicrobial
molecules, including proteins, vitamins, fatty acids, pigments, etc [61]. In addition, microalgae coexist
with other aquatic organisms creating competitive relationships that provoke them to synthetize
or secrete several substances and/or molecules in order to inhibit their competitors [62]. It has
been reported that some of these products have antimicrobial activity [62]. Among the compounds
presenting antimicrobial activity discovered from marine organisms we can find alkaloids, terpenoids,
lipids, peptides, halogenated compounds, polyketides, isocumarins, and nucleosides [63,64]. However,
studies about antibiofilm activity of substances produced by microalgae are scarce.
Due to the global problem of antimicrobial resistance and the importance of bacterial forming
biofilm as the cause of the most infections, there is an urgent need for new bioactive compounds with
antibiofilm activity.
5. Antibiofilm Activity of Compounds Isolated from Microalgae.
Several studies have described compounds produced by microalgae and cyanobacteria species
with antimicrobial activity. However, studies on the antibiofilm activity of extracts and/or molecules
produced by these microorganisms are scarce.
An important phase in the extraction methods of active compounds from microalgae is the choice
of solvent. Crude microalgae extracts are a heterogeneous mixture of polar and non-polar compounds.
The selection of an efficient method of extraction is important for performing successive assays. The
solvents commonly used in this practice are hexane, chloroform, and petroleum ether (non-polar
solvents), and ethyl acetate, methanol, acetone, and dichloromethane (polar solvents). A wide range
of biological samples can be extracted in order to collect the greatest range of polar and non-polar
compounds. For example, hexane can extract polar compounds, such as triacylglycerides (TAG), while
polar solvents such as methanol and ethyl acetate can extract a wide variety of biological compounds
(polar and non-polar metabolites) such as fatty acids (FA) [65].
Among the studies available in the literature, the study by Lauritano and col. should be
highlighted [66]. The objective of their research was to find compounds with different biological
activities, including antibacterial and antibiofilm activities from crude extracts of 32 microalgal species,
including diatoms, dinoflagellates, and flagellates. Among these species, while the Leptocylindrus genus
did not show cytotoxicity in previous antibacterial tests, it has strong antibiofilm activity, inhibiting 90%
of S. epidermidis when the microalgae are grown under stress conditions caused by nitrogen starvation.
Therefore, this environmental stress could be the reason for the greater production of molecules with
antagonistic activity against clinically important bacteria.
Recently, in the NoMorFilm project in 2019, Cepas and col. [67], investigated the antibiofilm
activity of 675 extracts from 225 microalgae and cyanobacteria species, including the phylum Cercozoa,
Charophyta, Chlorophyta, Cryptophyta, Cyanobacteria, Euglenophyta, Glaucophyta, Haptophyta,
Miozoa, Ochrophyta, Rhodophyta, and two unknown phyla, against clinically important bacterial and
fungal pathogens.
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In this work, the extraction method consisted of three different solvents (hexane [non-polar],
ethyl acetate [polar], and methanol [polar]) for extracting a wide range of biological samples. The
highest inhibition ratios of extracts from all the solvents were found against C. albicans and E. cloacae.
Interestingly, C. albicans showed high inhibition rates above 50% in all the samples, with the exception
of Glaucophyta and Miozoa methanol extracts (28.2% and 12.55%, respectively) and Rhodophyta
hexane extracts (34.77%). In the case of E. cloacae, the biofilm inhibition ratios were 35%, and only the
methanol extract from the Miozoa phylum showed activity below 35% (9.38%). (Figure 5)
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Figure 5. Circular dot pl t representing the biofilm inhibition ratio (%) of each bacterium in relation
to the solvent employed (ethyl acetate, hexan , d methanol), according to the microalgae and
cyanob cteria phylum. CAL: C. albicans; CPA: C. parapsilopsis; ECO: E. coli; SHO: S. hominis; ECL:
E. cloacae; KPE: K. pneumoniae; PAE: P. aeruginosa; SAU: S. aure s; SEP: S. epidermidis. [67].
On the other hand, Chlorophyta and Charophyta extracts showed higher minimal biofilm inhibitory
concentration (MBIC) values than the other phyla. Curiously, the Chlorophyta phylum is known for its
ability to synthesize a variety of bioactive compounds such as lipids and derivative polyunsaturated
fatty acids (PUFAs). Specifically, two PUFAs, docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA), have demonstrated to exhibit antibacterial and antibiofilm properties [68,69]. However, in this
study, their presence was not evident.
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An important focus in the search for eco-friendly bioactives is to investigate molecules that have
the cell-cell communication system responsible for population density as a target. It is well-known
that bacteria present inside biofilm communicate with each other through signalling molecules called
autoinducers in response to population density. This process is known as quorum sensing (QS) [3,70].
Gram-negative and Gram-positive bacteria use acylated homoserine lactones and oligopeptides as
autoinducers which induce the expression of QS genes [71,72].
In this sense, the freshwater green microalgae Chlorella vulgaris produces a high variety of
bioactive compounds with important nutritional qualities and interesting therapeutic properties.
Studies using Chlorella mainly demonstrated its antitumoural effects, cancer chemoprevention
properties, anti-inflammatory activity, antioxidant activity, immune system activation, antimicrobial,
and antibiofilm activity [73].
Taking into account this background, Varsha Gayatri and col, [50] from the Valliammal College
for Women in India, investigated the antibiofilm effect of Chlorella vulgaris ethanolic extracts on biofilm
development and QS inhibition. The results of this investigation, showed that the inhibition of biofilm
formation by these ethanolic extracts was around 85% in P. aeruginosa at a concentration of 2 mg/mL,
80% at 1 mg/mL, 75% at 0.5 mg/mL, 70% at 0.25 mg/mL, 65% at 0.125 mg/mL, and 60% at 0.0625 mg/mL.
In addition, scanning electron microscope (SEM) showed a significant reduction in biofilm formation
at a concentration of 1 mg/mL, demonstrating this inhibitory activity.
Interestingly, the ethanolic extracts were able to dramatically reduce the biofilm without inhibiting
growth, which was associated with an interruption of “sensing” but not with a reduction of “quorum”.
Analysis by gas-chromatography and mass spectro-photometry (GS–MS) revealed that diethyl phthalate
at Rt 15.563 (39.28%) and trimethyl (4-tertbutyl phenoxy) silane at Rt 31.944 (25.63%), were the major
compounds in the ethanolic extract of C. vulgaris, and could play an important role in antibiofilm
strategies against multidrug-resistant P. aeruginosa. Similar results were found in 2015 by Lewis Oscar.
and col. [55] who observed that the Spirulina extract has strong inhibitory biofilm formation activity
but does not exhibit antibacterial activity.
In addition, researchers from India, [74] determined the antibiofilm activity of methanolic extracts
of C. vulgaris against P. aeruginosa and S. aureus. Treatments of 1.0, 0.5, and 0.25 mg/mL of this
extract showed significant reductions of biofilm formation in P. aeruginosa (82.5%, 56.5%, and 46.5%,
respectively) and in S. aureus (88.0%, 58.5%, and 48.0%, respectively).
Another important area of research is oral health. Dental caries are the result of activities of
bacterial strains [75]. The main microorganisms associated with tooth caries are Streptococcus mutans
and Lactobacillus sp. The erosion of tooth enamel by bacteria is due to the generation of acids as a result
of the metabolism of sugar fermentation, and the ability that these microorganisms can withstand
acidic conditions in dental plaque [76]. Furthermore, the development of biofilm formation associated
with S. mutans could explain the appearance of a variety of diseases in the oral cavity. In this sense, the
ethanolic extracts of C. vulgaris and D. salina could contribute to the inhibition of biofilm formation.
The 2019 disc diffusion results of Jafari [77] showed the antimicrobial activity of C. vulgaris extract
against S. mutants at concentrations of 2.5 mg/disc, producing a large inhibition zone with a diameter
of 13.5 ± 0.92 mm. In the case of a D. salina extract, a concentration of 6 mg/disk showed an inhibition
diameter of 18.5 ± 0.97 mm. With respect to antibiofilm activity, a C. vulgaris extract showed antibiofilm
activity at a concentration of 4 mg/mL, while for the D. salina extract 2 mg/mL was necessary to
inhibit biofilm formation. Although C. vulgaris and D. salina have been investigated by many authors
broadly for their biological activity [78], this was the first study to demonstrate the effects of these
microalgae against viability and biofilm formation of S. mutans. According to the analysis of the
extracts, the authors suggested that flavonoids, tannins, and terpenoids from C. vulgaris extract and
3,3,5-trimethylheptane, n-hexadecane together with PUFAs and β-ionone and neophytadiene (related
to carotene metabolism) from D. salina extract might be responsible for antimicrobial properties. On the
other hand, the suppressive activity of glucosyltransferases (GTF) from C. vulgaris and D. salina might
be attributed to the antibiofilm activity.
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Currently, nanotechnology is becoming increasingly used in the exploration of different fields
such as chemistry, biology, physics, materials science, and engineering. The production of nanodevices
has been useful in various applications and could be a very attractive tool for the treatment of certain
infectious diseases. In the general context, the unique properties possessed by nano-materials are a
result of their small size (range from 0.1 to 100 nm) and the large surface to volume ratio and definite
quantum confinement. [79,80].
Production of nanoparticles can be achieved through traditional physical, biological and chemical
methods, with the last method commonly involving the use of toxic chemicals. However, the main
challenge of nanotechnology today is the biosynthetic production of eco-friendly nanoparticles which
do not represent a threat to the environment or humans as a result of their administration [81,82].
Silver nanoparticles (AgNPs) have shown outstanding antimicrobial properties unlike standard
antimicrobial agents. Low doses of silver nanoparticles are needed for the treatment of infectious
diseases. Their high antimicrobial activity against Gram-negative and Gram-positive strains is mainly
due to the release of silver ions, which act as potential destroyers of microbial cells, generating an
alteration of cell permeability followed by cell lysis and apoptosis [83,84].
Along the “eco-friendly”line, in 2018 Adebayo-Tayo and colleagues [82] worked on the biosynthesis
of silver nanoparticles containing methanol extract of the Oscillatoria sp green algae. The results of
this research showed the biosynthesized OsSNPs to have strong antibacterial activity against seven
clinical pathogenic bacteria (S. aureus ATCC29213, E. coli ATCC 11775, E. coli ATCC 35218, P. aeruginosa
ATCC27853, Citrobacter sp., S. typhi ATCC 14028, and Bacillus cereus) at 24, 48, and 72 h. The inhibition
zone ranged between 6 mm for B. cereus to 20 mm for E. coli. In addition, studies with Oscillatoria sp.
extract showed antibacterial activity against other pathogenic bacteria with an inhibition range from
13–24 mm, with the highest activity being against P. aeruginosa. In addition, these OsSNPs showed
strong antibiofilm activity against all the pathogens used in the study. The highest biofilm inhibition
was observed against P. aeruginosa ATCC 27853 while the lowest inhibition was against Citrobacter sp.
Another study in the “eco-friendly” line was carried out by Vijayan and col. in 2014, [85]. They
observed that after 24 h of incubation, the AgNPs associated with aqueous extract of Turbinaria conoides
(macroalgae) inhibited the adherence and biofilm formation of Salmonella sp., E. coli, Serratialique faciens,
and Aeromonas hydrophila at very low concentrations.
The use of nanoparticles in the discovery of new compounds with antibiofilm activity has been
reported previously by other authors. In 2013, Martinez-Gutierrez and colleagues [86] evaluated the
antibiofilm activity of AgNPs against biofilms generated on membranes under static and high fluid
conditions. The bacterial strains evaluated were P. aeruginosa, A. baumannii, MRSA (as colonizer of
medical devices), S. mutans and C. albicans (as cariogenic and periodontopathogenic pathogens). The
results of this work showed an important reduction of 4-log in the number of colony-forming units?? of
biofilm in P. aeruginosa exposed to 500 mg/mL of AgNPs and a 6-log reduction when the concentration of
the AgNPs was increased to 1000 mg/mL. In addition, important results were found with A. baumannii,
observing a reduction of 3.5–4-log when cells were exposed to AgNPs concentrations between 250 and
1000 mg/mL. A reduction of only 1-log was observed in the remaining microbial strains.
6. Conclusions
Many different compounds with important antibacterial and antibiofilm properties have been
isolated from microalgae. However, studies on the mechanisms of action and toxicity of these
compounds are needed. An interesting line of research with promising results is the study of
metabolites synthesized by natural organisms such as marine microalgae. These molecules could
increase their power of action through the use of tools such as nanotechnology and could be useful for
preventing and treating biofilm-related infections.
Antibiotics 2020, 9, 9 12 of 16
7. Future Aspects
Marine organisms, including microalgae, are one of the most important sources of biomolecules
with antimicrobial and anticancer activities, among others that could be useful for the treatment and
prevention of many human diseases. Nonetheless, one of the problems with these molecules is the
small amount in which they are present in the extracts. For this reason, it is necessary to determine
different ways to increase the production of these molecules. Taking this into account, new molecular
biology techniques such as CRISP/Cas9 and genomic studies could help to obtain larger amounts of
molecules without the need for a high amount of reagents and time, thereby decreasing the costs
associated with this production.
To achieve this, collaboration among research groups from different disciplines (chemistry, biology,
microbiology, etc.) is needed to identify these molecules and new processes to improve their production
without effects against their natural sources. In addition, the pharmaceutical industry should become
more involved in supporting the development of the new molecules to reach the market.
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